Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities

Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, Prateek Srivastava, Shailendra P. Singh, Salomon Amar

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)


There are substantial shortcomings in the drugs currently available for treatment of type 2 diabetes mellitus. The global diabetic crisis has not abated despite the introduction of new types of drugs and targets. Persistent unaddressed patient needs remain a significant factor in the quest for new leads in routine studies. Drug discovery methods in this area have followed developments in the market, contributing to a recent rise in the number of molecules. Nevertheless, troubling developments and fresh challenges are still evident. Recently, metformin, the most widely used first-line drug for diabetes, was found to contain a carcinogenic contaminant known as N-nitroso dimethylamine (NDMA). Therefore, purity and toxicity are also a big challenge for drug discovery and development. Moreover, newer drug classes against SGLT-2 illustrate both progress and difficulties. The same was true previously in the case of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Furthermore, researchers must study the importance of mechanistic characteristics of novel compounds, as well as exposure-related hazardous aspects of current and newly identified protein targets, in order to identify new pharmacological molecules with improved selectivity and specificity.

Original languageEnglish
Article number331
Issue number2
Publication statusPublished - 31-01-2022

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities'. Together they form a unique fingerprint.

Cite this